The state of innovation
21 July, 2014The Global Innovation Index 2014 has ranked Australia 17th out of 143 economies for having a well-linked innovation ecosystem.
Starpharma close to first major revenues
21 July, 2014 by Dylan Bushell-EmblingAnsell has secured Australian certification for a line of condoms coated with Starpharma's (ASX:SPL) VivaGel, and aims to launch a line of products in the next few months.
Annual global biotech report released
17 July, 2014EY's annual report on the global biotechnology industry shows the industry rebounded strongly in 2013, with public companies achieving double-digit revenue growth and a sharp rise in funds raised. Product successes have boosted revenues, drawn investors and motivated large companies to invest strongly in R&D.
Calzada announces organisational revamp
16 July, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) plans an organisational restructuring involving appointing a managing director for its PolyNovo business and recruiting new clinical, regulatory, commercial and manufacturing talent.
Personalised medicine start-up DoseMe raises $500K
15 July, 2014 by Dylan Bushell-EmblingBrisbane-based start-up DoseMe has picked up $500K in investment funding to expand the market reach and supported medications for its personalised dosage calculation software.
New council of international biotech associations formed
15 July, 2014An international confederation of biotechnology trade associations, with membership across six continents, has created the International Council of Biotechnology Associations (ICBA), with the expressed purpose of advocating for public policies that support the global growth of the innovative biotechnology industry.
Phosphagenics raising $19.3m for TPM trials
14 July, 2014 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has launched a $19.3m capital raising to fund trials for its two TPM/opioid patches as the company ramps up its commercialisation efforts.
FDA approves StarPharma's VivaGel trial design
14 July, 2014 by Dylan Bushell-EmblingThe US FDA has granted Starpharma (ASX:SPL) a Special Protocol Assessment for the design of two phase III trials of VivaGel for the prevention of recurrent bacterial vaginosis.
Prima appoints new CEO to reflect European focus
11 July, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR), having centralised its clinical and manufacturing operations in Europe, has promoted its head of European operations to CEO.
Rhinomed partners to promote Turbine device
10 July, 2014 by Dylan Bushell-EmblingRhinomed (ASX:RNO) has announced a partnership to promote its fitness breathing device Turbine at Fitness First gyms and revealed that sales of the device hit $201K during the June quarter.
NSW medical devices commercial training program open for early-career postgraduates
10 July, 2014Expressions of interest are invited for a new training program that will arm early-career postgraduate researchers involved in medical technology and product-related research with the necessary entrepreneurial skills to successfully commercialise a medical technology.
Antisense wins Canadian patent for IGF-I modulator
09 July, 2014 by Dylan Bushell-EmblingAntisense Therapeutics has picked up a Canadian patent covering ATL1103 - a potential treatment for growth disorders including acromegaly - and has dosed 24 patients in a phase II trial.
QRxPharma chair, three directors step down
09 July, 2014 by Dylan Bushell-EmblingFour QRxPharma (ASX:QRX) board members, including chairman Dr Peter Farrell, have resigned hours before a board-spill vote called by a group of unhappy shareholders.
AusBiotech July journal features 'manufacturing, money and medtech'
08 July, 2014The latest edition of AusBiotech's journal, Australasian Biotechnology (July 2014, Volume 24, Number 2), is out now.
NeuClone signs biosimilar deal with Serum Institute
07 July, 2014 by Dylan Bushell-EmblingSydney's NeuClone has entered a global partnership with The Serum Institute of India to produce a portfolio of 10 biosimilar monoclonal antibody drugs.
